NovaBridge Biosciences (NBP) Operating Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Operating Leases data on file, last reported at $2.2 million in Q4 2025.

• Quarterly Operating Leases rose 470.07% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 470.07% YoY) and the FY2025 annual result came in at $2.2 million, up 470.07% from the prior year.
• Operating Leases advanced to $2.2 million in Q4 2025 per NBP's latest filing, from -$608000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $12.8 billion in Q4 2021 and bottomed at -$2.6 million in Q2 2022.
• The 5-year median for Operating Leases is $2.6 million (2025), against an average of $985.4 million.
• The widest annual swing landed in 2021, when Operating Leases jumped 1529598.65%; it then tumbled 153.56% in 2022.
• Tracing NBP's Operating Leases over 5 years: stood at $12.8 billion in 2021, then sank by 99.96% to $4.5 million in 2022, then decreased by 28.85% to $3.2 million in 2023, then slumped by 118.33% to -$588000.0 in 2024, then jumped by 470.07% to $2.2 million in 2025.
• Per Business Quant, the three latest NBP Operating Leases figures stand at $2.2 million (Q4 2025), -$608000.0 (Q3 2025), and $2.6 million (Q2 2025).

Peer Comparison